Supplementary Figure S4: Forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with disease free survival on the capecitabine arm vs. observation. Expression status was derived from the median gene expression scores. Hazard ratios, 95% confidence intervals and *P*-values are derived from Cox regression analyses adjusted for age, menopausal status, histological grade, tumor size, stage, breast surgery, region, nodal status, and chemotherapy regimen. The displayed *P*-interaction indicates results of test of heterogeneity.

Supplementary Figure S4

Subgroup	HR, 95%CI	P.value	P.interaction
Cytotoxic cells			0.69
High	0.71 (0.44–1.16)	0.17	
Low	0.69 (0.45–1.06)	0.09	
Mast cells			0.6
High	0.7 (0.46–1.08)	0.15	
Low	0.86 (0.54–1.36)	0.52	
Endothelial			0.76
High	0.79 (0.52–1.21)	0.28	
Low	0.69 (0.43–1.12)	0.13	
IL24			0.27
High	0.9 (0.58–1.4)	0.65	
Low	0.62 (0.4–0.98)	0.04	
IL22RA2			0.57
High	0.7 (0.44–1.11)	0.12	
Low	0.83 (0.54–1.28)	0.4	
NRCAM			0.14
High	0.6 (0.38–0.94)	0.03	
Low	0.88 (0.56–1.39)	0.59	
GRIA3			0.84
High	0.76 (0.48–1.18)	0.22	
Low	0.72 (0.46–1.12)	0.15	
SOCS3			0.62
High	0.6 (0.37–0.96)	0.03	
Low	0.79 (0.51–1.22)	0.28	
CXCL5			0.14
High	0.93 (0.6–1.44)	0.74	
Low	0.58 (0.36–0.91)	0.02	
VIT			0.95
High	0.75 (0.48–1.16)	0.19	
Low	0.73 (0.46–1.15)	0.17	
MME			0.7
High	0.79 (0.5–1.24)	0.31	
Low	0.67 (0.43–1.04)	0.08	
PLCB1			0.86
High	0.71 (0.47–1.09)	0.11	
Low	0.78 (0.48–1.25)	0.3	
SLC28A1			0.84
High	0.64 (0.39–1.05)	0.07	
Low	0.73 (0.48–1.12)	0.15	
CTSW			0.89
High	0.68 (0.42–1.09)	0.11	
Low	0.79 (0.51–1.21)	0.27	
CES1			0.17
High	0.59 (0.38–0.93)	0.02	
Low	0.96 (0.61–1.51)	0.85	
BMP2			0.92
High	0.76 (0.48–1.2)	0.24	
Low	0.68 (0.43–1.06)	0.09	
GZMH			0.76
High	0.74 (0.46–1.18)	0.2	
Low	0.73 (0.48–1.12)	0.15	
TGFB2			0.67
High	0.72 (0.46–1.11)	0.13	
Low	0.76 (0.48–1.19)	0.23	
HAS1			0.69
High	0.83 (0.54–1.28)	0.4	
Low	0.7 (0.44–1.13)	0.14	
CCNA1			0.58
High	0.8 (0.52–1.24)	0.32	
Low	0.7 (0.45–1.1)	0.12	

<---Capecitabine Better--- ---Observation Better--->

Subgroup	HR, 95%CI	P.value	P.interaction
CXCL10			0.69
High	0.64 (0.39–1.05)	0.08	
Low	0.78 (0.52–1.18)	0.24	
IL6			0.38
High	0.63 (0.41–0.97)	0.03	
Low	0.89 (0.56–1.42)	0.64	
CCR5			0.27
High	0.58 (0.36–0.93)	0.02	
Low	0.93 (0.6–1.42)	0.73	
CACNA2D3			0.77
High	0.77 (0.49–1.22)	0.27	
Low	0.7 (0.46–1.08)	0.11	
JAK1			0.28
High	0.57 (0.36–0.91)	0.02	
Low	0.93 (0.6–1.45)	0.75	
HOXA9			0.5
High	0.87 (0.56–1.35)	0.53	
Low	0.71 (0.44–1.14)	0.15	
TWIST2			0.33
High	0.88 (0.57–1.35)	0.54	
Low	0.64 (0.41–1.02)	0.06	
PDL2			0.47
High	0.64 (0.4–1.02)	0.06	
Low	0.86 (0.56–1.32)	0.5	
BCL2A1			0.52
High	0.67 (0.42–1.08)	0.1	
Low	0.82 (0.54–1.25)	0.36	
ANGPT1			0.53
High	0.86 (0.56–1.3)	0.47	
Low	0.67 (0.41–1.09)	0.11	
LIFR			0.99
High	0.79 (0.51–1.24)	0.31	
Low	0.76 (0.48–1.19)	0.23	
IDO1			0.72
High	0.68 (0.42–1.1)	0.11	
Low	0.8 (0.53–1.22)	0.3	
PSMB9			0.92
High	0.68 (0.41–1.11)	0.12	
Low	0.75 (0.49–1.15)	0.18	
LEP			0.53
High	0.84 (0.55–1.29)	0.43	
Low	0.68 (0.43–1.09)	0.11	
STC1			0.02
High	0.54 (0.35–0.82)	0.003	
Low	1.19 (0.74–1.93)	0.47	
VIM			0.94
High	0.73 (0.46–1.15)	0.17	
Low	0.76 (0.49–1.19)	0.23	
KLRK1			0.74
High	0.67 (0.41–1.1)	0.11	
Low	0.79 (0.52–1.2)	0.26	
PDL1			0.72
High	0.77 (0.47–1.24)	0.27	
Low	0.73 (0.48–1.1)	0.13	
TYMP			0.72
High	0.75 (0.46–1.22)	0.24	
Low	0.7 (0.46–1.07)	0.10	
STAT1			0.74
High	0.79 (0.49–1.27)	0.33	
Low	0.74 (0.49–1.13)	0.17	
NKG7			0.67
High	0.65 (0.4–1.06)	0.08	
Low	0.81 (0.53–1.23)	0.32	

<---Capecitabine Better--- ---Observation Better--->